With nearly 40 million people living with HIV globally, mounting evidence pointed to the benefits of dolutegravir (TLD) over efavirenz (TLE). WHO needed to determine whether the evidence base supported switching regimens from a public health perspective.
Over a decade of SLRs and NMAs comparing TLE with TLD regimens across outcomes.
Informed WHO’s decision to recommend TLD worldwide, resulting in more than 20 million people switching regimens and multiple Lancet HIV publications.